TEVA Stock Analysis: Buy, Sell, or Hold?
TEVA - Teva Pharmaceutical Industries Limited American Depositary Shares
$37.09
0.74 (2.04%)
â˛
5d:
+1.28%
30d:
+0.95%
90d:
+7.32%
WAIT
LOW Confidence
Analysis Updated: Sep 11, 2026 12:00 AM ET
Earnings: Nov 04, 2026
Get Alerted When TEVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: TEVA is fairly priced but lacks strong directional signals. At 3.6% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: TEVA is fairly priced but lacks strong directional signals. At 3.6% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$65.15
Based on 14.5% avg growth
INTRINSIC VALUE TODAY
$40.45
8.3% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.9x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: TEVA is currently trading at $37.09, which is considered slightly high relative to its 30-day fair value range of $35.54 to $37.42. From a valuation perspective, the stock is trading at a premium (Forward PE: 12.1) compared to its historical average (10.9). At these levels, the market is pricing in 3.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, TEVA is in a uptrend. The price is approaching resistance at $38.06. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TEVA scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $41.91 (+13.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, TEVA is in a uptrend. The price is approaching resistance at $38.06. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: TEVA scores 32/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $41.91 (+13.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$35.54 -
$37.42
Company Quality Score
44/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
41.4%
All Signals
- BEARISH: Weak technical setup (32/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($41.91)
- NEUTRAL: Market pricing in 3.6% annual earnings growth - fairly valued
- WARNING: Composite score 44/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$35.54 -
$37.42
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$35.42
Resistance Level
$38.06
Current Trend
Uptrend
Technical data as of
Sep 11, 2026
Fundamental Context
Forward P/E (Next Year Est.)
12.08
Wall Street Target
$41.91
(+13.0%)
Revenue Growth (YoY)
-0.8%
Earnings Growth (YoY)
72.2%
Profit Margin
4.1%
Valuation Premium vs History
+3.6% premium
PE vs Historical
12.1 vs 10.9
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+3.6%
(market-implied from PE analysis)
1-Year Target
$38.43
(+4%)
2-Year Target
$39.81
(+7%)
3-Year Target
$41.24
(+11%)
3-Yr Target (if PE normalizes)
(PE: 12â11)
PE COMPRESSION
$37.20
(+0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.2, Growth: 44.2%)
$185.47
(+400%)
Base:
(SPY PE: 12.1, Growth: 44.2%)
$111.12
(+200%)
Bear:
(PE: 10.3, Growth: 44.2%)
$94.45
(+155%)
đ
Valuation based on Current Earnings
Forward PE: 11.95 | Forward EPS (Implied): $3.10
Bull Case
$44.79
(+21%)
Analyst growth 15.0%, PE expands to 12.5
Base Case
$37.09
(0%)
Market implied 0.0%, PE stable at 12.0
Bear Case
$28.37
(-24%)
Severe decline -15.0%, PE contracts to 10.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: September 13, 2026 12:44 PM ET
Data refreshes hourly during market hours. Next update: 1:44 PM
Data refreshes hourly during market hours. Next update: 1:44 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TEVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$211 | 60 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 70 BUY |
|
INDV
Indivior PLC Ordinary ShâĻ |
STRONG BUY
7 analysts |
$49 | 69 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 46 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 47 HOLD |
